207 related articles for article (PubMed ID: 36445704)
21. Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer.
Tarantino P; Jin Q; Tayob N; Jeselsohn RM; Schnitt SJ; Vincuilla J; Parker T; Tyekucheva S; Li T; Lin NU; Hughes ME; Weiss AC; King TA; Mittendorf EA; Curigliano G; Tolaney SM
JAMA Oncol; 2022 Aug; 8(8):1177-1183. PubMed ID: 35737367
[TBL] [Abstract][Full Text] [Related]
22. Comparison of Management and Outcomes in ERBB2-Low vs ERBB2-Zero Metastatic Breast Cancer in France.
de Calbiac O; Lusque A; Mailliez A; Bachelot T; Uwer L; Mouret-Reynier MA; Emile G; Jouannaud C; Gonçalves A; Patsouris A; Diéras V; Leheurteur M; Petit T; Cottu P; Ferrero JM; D'Hondt V; Desmoulins I; Mourato-Ribeiro J; Martin AL; Frenel JS
JAMA Netw Open; 2022 Sep; 5(9):e2231170. PubMed ID: 36107428
[TBL] [Abstract][Full Text] [Related]
23. The economic burden of metastatic breast cancer in Spain.
Bermejo de Las Heras B; Cortes Ramon Y Cajal J; Galve Calvo E; de la Haba Rodriguez J; Garcia Mata J; Moreno Anton F; Pelaez Fernandez I; Rodriguez-Lescure A; Rodriguez Sanchez CA; Ruiz-Borrego M; Remak E; Barra M; Rivero M; Soto Alvarez J
Eur J Hosp Pharm; 2020 Jan; 27(1):19-24. PubMed ID: 32064084
[TBL] [Abstract][Full Text] [Related]
24. Real-World Analysis of Medical Costs and Healthcare Resource Utilization in Elderly Women with HR+/HER2- Metastatic Breast Cancer Receiving Everolimus-Based Therapy or Chemotherapy.
Hao Y; Li N; Fang AP; Koo V; Peeples M; Kageleiry A; Wu EQ; Guérin A
Adv Ther; 2016 Jun; 33(6):983-97. PubMed ID: 27216253
[TBL] [Abstract][Full Text] [Related]
25. Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort.
Grinda T; Antoine A; Jacot W; Blaye C; Cottu PH; Diéras V; Dalenc F; Gonçalves A; Debled M; Patsouris A; Mouret-Reynier MA; Mailliez A; Clatot F; Levy C; Ferrero JM; Desmoulins I; Uwer L; Petit T; Jouannaud C; Lacroix-Triki M; Deluche E; Robain M; Courtinard C; Bachelot T; Brain E; Pérol D; Delaloge S
ESMO Open; 2021 Jun; 6(3):100114. PubMed ID: 33895695
[TBL] [Abstract][Full Text] [Related]
26. Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial.
Symmans WF; Yau C; Chen YY; Balassanian R; Klein ME; Pusztai L; Nanda R; Parker BA; Datnow B; Krings G; Wei S; Feldman MD; Duan X; Chen B; Sattar H; Khazai L; Zeck JC; Sams S; Mhawech-Fauceglia P; Rendi M; Sahoo S; Ocal IT; Fan F; LeBeau LG; Vinh T; Troxell ML; Chien AJ; Wallace AM; Forero-Torres A; Ellis E; Albain KS; Murthy RK; Boughey JC; Liu MC; Haley BB; Elias AD; Clark AS; Kemmer K; Isaacs C; Lang JE; Han HS; Edmiston K; Viscusi RK; Northfelt DW; Khan QJ; Leyland-Jones B; Venters SJ; Shad S; Matthews JB; Asare SM; Buxton M; Asare AL; Rugo HS; Schwab RB; Helsten T; Hylton NM; van 't Veer L; Perlmutter J; DeMichele AM; Yee D; Berry DA; Esserman LJ
JAMA Oncol; 2021 Nov; 7(11):1654-1663. PubMed ID: 34529000
[TBL] [Abstract][Full Text] [Related]
27. Impact of Nonconcordance With NCCN Guidelines on Resource Utilization, Cost, and Mortality in De Novo Metastatic Breast Cancer.
Rocque GB; Williams CP; Jackson BE; Ingram SA; Halilova KI; Pisu M; Kenzik KM; Azuero A; Forero A; Bhatia S
J Natl Compr Canc Netw; 2018 Sep; 16(9):1084-1091. PubMed ID: 30181420
[No Abstract] [Full Text] [Related]
28. Clinical and economic outcomes by first-line treatment among women with HR+/HER2- metastatic breast cancer in a large US health plan database.
Burton T; Byfield SD; Smith GL; Zanotti G; Bell TJ; Perkins JJ; Horblyuk R; Teitelbaum A
Curr Med Res Opin; 2016 Aug; 32(8):1417-23. PubMed ID: 27074160
[TBL] [Abstract][Full Text] [Related]
29. Analysis of costs associated with administration of intravenous single-drug therapies in metastatic breast cancer in a U.S. population.
Kruse GB; Amonkar MM; Smith G; Skonieczny DC; Stavrakas S
J Manag Care Pharm; 2008; 14(9):844-57. PubMed ID: 19006441
[TBL] [Abstract][Full Text] [Related]
30. Treatment patterns and duration in post-menopausal women with HR+/HER2- metastatic breast cancer in the US: a retrospective chart review in community oncology practices (2004-2010).
Macalalad AR; Hao Y; Lin PL; Signorovitch JE; Wu EQ; Ohashi E; Zhou Z; Kelley C
Curr Med Res Opin; 2015 Feb; 31(2):263-73. PubMed ID: 25350226
[TBL] [Abstract][Full Text] [Related]
31. A population-based comparison of treatment patterns, resource utilization, and costs by cancer stage for Ontario patients with triple-negative breast cancer.
Brezden-Masley C; Fathers KE; Coombes ME; Pourmirza B; Xue C; Jerzak KJ
Cancer Med; 2020 Oct; 9(20):7548-7557. PubMed ID: 32862501
[TBL] [Abstract][Full Text] [Related]
32. Association of Low Nodal Positivity Rate Among Patients With ERBB2-Positive or Triple-Negative Breast Cancer and Breast Pathologic Complete Response to Neoadjuvant Chemotherapy.
Barron AU; Hoskin TL; Day CN; Hwang ES; Kuerer HM; Boughey JC
JAMA Surg; 2018 Dec; 153(12):1120-1126. PubMed ID: 30193375
[TBL] [Abstract][Full Text] [Related]
33. Comparison of outcomes between metaplastic and triple-negative breast cancer patients.
Polamraju P; Haque W; Cao K; Verma V; Schwartz M; Klimberg VS; Hatch S; Niravath P; Butler EB; Teh BS
Breast; 2020 Feb; 49():8-16. PubMed ID: 31675684
[TBL] [Abstract][Full Text] [Related]
34. Time on treatment of everolimus and chemotherapy among postmenopausal women with hormone-receptor-positive/human-epidermal-growth-factor-receptor-2-negative metastatic breast cancer: a retrospective claims study in the US.
Li N; Hao Y; Kageleiry A; Peeples M; Fang A; Koo V; Wu EQ; Guérin A
Curr Med Res Opin; 2016; 32(2):385-94. PubMed ID: 26651842
[TBL] [Abstract][Full Text] [Related]
35. Association of Adjuvant Hormone Therapy Timing With Overall Survival Among Patients With Hormone Receptor-Positive Human Epidermal Growth Factor Receptor-2-Negative Early Breast Cancer Without Chemotherapy.
Fu F; Yu L; Zeng B; Chen M; Guo W; Chen L; Lin Y; Hou J; Li J; Li Y; Li S; Chen X; Zhang W; Jin X; Cai W; Zhang K; Chen H; Qiu Y; Nie Q; Wang C; Jacobs L
JAMA Netw Open; 2022 Feb; 5(2):e2145934. PubMed ID: 35166783
[TBL] [Abstract][Full Text] [Related]
36. Patient-reported Quality of Life and Treatment Satisfaction in Patients With HR
Wood R; Mitra D; de Courcy J; Iyer S
Clin Ther; 2017 Aug; 39(8):1719-1728. PubMed ID: 28751098
[TBL] [Abstract][Full Text] [Related]
37. Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014.
Schroeder MC; Rastogi P; Geyer CE; Miller LD; Thomas A
Oncologist; 2018 Apr; 23(4):481-488. PubMed ID: 29330212
[TBL] [Abstract][Full Text] [Related]
38. Breast-conserving therapy for triple-negative breast cancer.
Gangi A; Chung A; Mirocha J; Liou DZ; Leong T; Giuliano AE
JAMA Surg; 2014 Mar; 149(3):252-8. PubMed ID: 24382582
[TBL] [Abstract][Full Text] [Related]
39. Economic Burden of HR+/HER2- Metastatic Breast Cancer Among Adult Premenopausal Women.
Gauthier G; Gagnon-Sanschagrin P; Guérin A; Burne R; Small T; Niravath P; Dalal AA
Adv Ther; 2018 Apr; 35(4):503-514. PubMed ID: 29556908
[TBL] [Abstract][Full Text] [Related]
40. Clinicopathologic Characteristics and Prognosis of ERBB2-Low Breast Cancer Among Patients in the National Cancer Database.
Peiffer DS; Zhao F; Chen N; Hahn OM; Nanda R; Olopade OI; Huo D; Howard FM
JAMA Oncol; 2023 Apr; 9(4):500-510. PubMed ID: 36821125
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]